{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:50Z","timestamp":1760782850741,"version":"3.32.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.neuropharm.2006.03.021","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T15:16:04Z","timestamp":1147446964000},"page":"251-262","source":"Crossref","is-referenced-by-count":23,"title":["QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine"],"prefix":"10.1016","volume":"51","author":[{"given":"Jos\u00e9","family":"Brea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e1n","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Isabel","family":"Loza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian F.","family":"Masaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Ravi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Dezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Cabrero-Castel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Gal\u00e1n-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Fern\u00e1ndez-Espejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2006.03.021_bib1","series-title":"Methods in Neurosciences","first-page":"366","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptor","author":"Ballesteros","year":"1994"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00436091","article-title":"Anti-psychotic drug effect on the behavior of squirrel monkeys differentially controlled by noxious stimuli","volume":"77","author":"Barrett","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.54.1.94","article-title":"Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus","volume":"54","author":"Berg","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/jm011014y","article-title":"New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones","volume":"45","author":"Brea","year":"2002","journal-title":"J. Med. Chem."},{"year":"1999","series-title":"AMBER6","author":"Case","key":"10.1016\/j.neuropharm.2006.03.021_bib5"},{"issue":"1","key":"10.1016\/j.neuropharm.2006.03.021_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0278-5846(97)00184-X","article-title":"Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice","volume":"22","author":"Curzon","year":"1998","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib7","first-page":"139","article-title":"Psychopharmacology of prepulse inhibition in mice","volume":"39","author":"Dulawa","year":"1996","journal-title":"Chin. J. Physiol."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(93)90036-D","article-title":"Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs","volume":"57","author":"Ellenbroek","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1021\/jm991056a","article-title":"Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists","volume":"43","author":"Elz","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib10","doi-asserted-by":"crossref","first-page":"D185","DOI":"10.1093\/nar\/gkh002","article-title":"ArchDB: automated protein loop classification as a tool for structural genomics","volume":"32","author":"Espadaler","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00213-004-1851-5","article-title":"Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor","volume":"175","author":"Fernandez-Espejo","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJM200201033460112","article-title":"Prevention of relapse in schizophrenia","volume":"346","author":"Geddes","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.mp.4001159","article-title":"Mouse genetic models for prepulse inhibition: an early review","volume":"7","author":"Geyer","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0031-9384(96)00503-3","article-title":"Involvement of dopamine receptors in the antipsychotic profile of (\u2212) eticlopride","volume":"61","author":"Giuliani","year":"1997","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0960-894X(02)00933-2","article-title":"New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors","volume":"13","author":"Gonzalez-Gomez","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4522(96)00036-X","article-title":"Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-d-aspartate receptors","volume":"73","author":"Hauber","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib18","first-page":"226","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/026988119701100205","article-title":"Dopamine, the prefrontal cortex and schizophrenia","volume":"11","author":"Knable","year":"1997","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0278-5846(92)90102-K","article-title":"Schizophrenia and the D1 receptor: focus on negative symptoms","volume":"16","author":"Lynch","year":"1992","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.pbb.2004.02.010","article-title":"The effect of SR141716 and apomorphine on sensiromotor gating in Swiss mice","volume":"77","author":"Malone","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0223-5234(00)00109-4","article-title":"Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D2, 5-HT2A, 5-HT2B, and 5-HT2C receptors","volume":"35","author":"Masaguer","year":"2000","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002130050434","article-title":"Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition","volume":"134","author":"McCaughran","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib25","first-page":"238","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0091-3057(00)00390-7","article-title":"Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol","volume":"67","author":"Meschler","year":"2000","journal-title":"Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","article-title":"Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H- [1] benzothieno [2,3-b] [1, 5]benzodiazepine maleate)","volume":"26","author":"Morimoto","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s002130100828","article-title":"The DBA\/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?","volume":"156","author":"Olivier","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002130100763","article-title":"Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?","volume":"156","author":"Ouagazzal","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib32","series-title":"Psychiatric Genetics and Genomics","first-page":"247","article-title":"Schizophrenia","author":"Owen","year":"2002"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-199651060-00001","article-title":"Adverse effects of antipsychotic agents. Do newer agents offer advantages?","volume":"51","author":"Owens","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.289.5480.739","article-title":"Crystal structure of rhodopsin: a G protein-coupled receptor","volume":"278","author":"Palczewski","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib35","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1523\/JNEUROSCI.22-21-09604.2002","article-title":"Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice","volume":"22","author":"Ralph-Williams","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.npp.1300017","article-title":"Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice","volume":"28","author":"Ralph-Williams","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","article-title":"Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor","volume":"299","author":"Rauser","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib38","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm981094e","article-title":"Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic 5-HT2A, 5-HT2C) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics","volume":"42","author":"Ravi\u00f1a","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib39","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1021\/jm0009890","article-title":"Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics","volume":"43","author":"Ravi\u00f1a","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(98)00019-9","article-title":"5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function","volume":"79","author":"Roth","year":"1998","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","article-title":"Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders","volume":"174","author":"Roth","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-004-1810-1","article-title":"Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment","volume":"175","author":"Russig","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.021_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modeling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0929867043456043","article-title":"New antipsychotics and schizophrenia: a review on efficacy and side effects","volume":"11","author":"Serretti","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","article-title":"DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors","volume":"6","author":"Sipes","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib47","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1523\/JNEUROSCI.20-24-09284.2000","article-title":"Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice","volume":"20","author":"Valverde","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.021_bib48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD. Proteins Struct","volume":"52","author":"Verdonk","year":"2003","journal-title":"Funct. Genet."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:22:28Z","timestamp":1736378548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390806000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0028390806000773"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2006.03.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}